| Patient | Vincent van Gogh |
|---|---|
| Date of birth | 1990-03-30 |
| Identifiers | MRN HR-NI010-SYN; SSN (made up) 000-10-3198 |
| Document date | 2026-03-02 |
| Author | Elise Verhoeven, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week review: symptoms, side effects, alcohol, sleep, and test results. [S]
Mr. van Gogh returns six weeks after his first visit and two weeks after the sick visit for akathisia, when aripiprazole went back to 10 mg and propranolol was started. The restlessness eased within three days and has been gone for more than a week. The night-time voices have not returned on 10 mg. He sleeps six and a half to seven hours. He is painting again for a few hours most days, which he says matters more to him than anything. He takes naltrexone daily and now has one or two glasses of wine on most evenings; he notices that he wants a second glass less. His mood is better, and the thoughts of not waking up have stopped. He meets the care coordinator weekly and has seen the therapist twice. [S]
| Element | Detail |
|---|---|
| Aripiprazole | 10 mg daily for two weeks, every dose taken |
| Akathisia | Resolved within three days; propranolol 10 mg twice daily |
| Psychotic symptoms | None |
| Sleep | Six and a half to seven hours |
| Alcohol | One or two glasses of wine most evenings |
| Mood | Better; PHQ-9 8; item 9 scored 0 |
| System | Result | Finding |
|---|---|---|
| Neurological | Negative | No restlessness, stiffness, tremor, seizures, or lost time |
| Cardiovascular | Negative | No dizziness or fainting on propranolol |
| Gastrointestinal | Negative | Mild nausea in the first days of naltrexone, now gone |
| Psychiatric | Negative | No voices or suspiciousness; mood improving; no thoughts of suicide or self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aripiprazole 10 mg oral tablet, one tablet by mouth once daily (started in hospital) | One tablet by mouth once daily | Oral route | 2026-01-05 to 2026-02-02 | completed | S |
| Aripiprazole 15 mg oral tablet, one tablet by mouth once daily | One tablet by mouth once daily | Oral route | 2026-02-02 to 2026-02-16 | completed | S |
| Naltrexone 50 mg oral tablet, one tablet by mouth once daily | One tablet by mouth once daily | Oral route | 2026-02-02 | active | S |
| Thiamine 100 mg oral tablet, one tablet by mouth daily (started in hospital) | One tablet by mouth daily | Oral route | 2026-01-05 to 2026-07-20 | completed | S |
| Aripiprazole 10 mg oral tablet, one tablet by mouth once daily | One tablet by mouth once daily | Oral route | 2026-02-16 | active | S |
| Propranolol 10 mg oral tablet, one tablet by mouth twice daily for akathisia | One tablet by mouth twice daily | Oral route | 2026-02-16 to 2026-03-02 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-02 | Body height | 170 | cm | S |
| 2026-03-02 | Body weight | 64.9 | kg | S |
| 2026-03-02 | Body mass index (BMI) [Ratio] | 22.5 | kg/m2 | S |
| 2026-03-02 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-03-02 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-03-02 | Heart rate | 76 | /min | S |
| 2026-03-02 | Respiratory rate | 14 | /min | S |
| 2026-03-02 | Body temperature | 36.6 | Cel | S |
| 2026-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-02 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 41 | U/L | 10-40 U/L | High | S |
| 2026-03-02 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 37 | U/L | 7-56 U/L | Normal | S |
| 2026-03-02 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 68 | U/L | 8-61 U/L | High | S |
| 2026-03-02 | Phosphatidylethanol [Mass/volume] in Blood | 122 | ng/mL | Below 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinking | High | S |
| 2026-03-02 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S |
Vital signs recorded on 2026-03-02; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 64.9 kg; blood pressure 120/76, pulse 76 |
| Neurological | No akathisia (Barnes global rating 0), rigidity, tremor, or abnormal movements |
| Psychiatric | Brighter affect; organized; no psychotic features; insight good |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| First episode of psychosis with mood features: weeks of very little sleep, intense work and expansive plans, then acute confusion, hallucinations and suspiciousness with self-injury, and low mood since discharge. Diagnosis provisional; differential: bipolar I disorder with psychotic features, brief psychotic or schizophreniform disorder, alcohol withdrawal delirium or alcohol-induced psychotic disorder, and psychosis related to focal epilepsy. Synthetic modern episode linked to his documented first crisis | active | provisional | F29 | S — Synthetic modern coding of the documented first crisis. Unspecified psychosis is coded because the cause is not yet established; the retrospective diagnoses stay in the claims. |
| Alcohol use disorder, moderate (heavy daily wine and anise spirits before the episode); synthetic modern episode linked to his documented heavy drinking | active | confirmed | F10.20 | S — Synthetic modern coding of the documented drinking and its retrospective interpretation. |
| Self-injury to the left ear during the acute confusional episode, without suicidal intent; wound healed after surgical care in hospital | active | confirmed | Z91.52 | S — Synthetic modern coding of the documented injury; no detail of the injury is recorded. |
| Akathisia from aripiprazole, two weeks after the dose was increased to 15 mg; treated by returning to 10 mg and short-term propranolol; resolved | resolved | confirmed | G25.71 | S — Synthetic medication side effect; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Antipsychotic dose, adherence, and response | Every visit | Completed today | Aripiprazole 10 mg since the sick visit; full adherence; remission of psychotic symptoms |
| Survey | Psychotic and mood symptoms, and early warning signs | Every visit | Completed today | No hallucinations or suspiciousness; no early warning signs |
| Examination | Akathisia, parkinsonism, and sedation | Every visit in the first months and after any dose change | Completed today | Akathisia resolved; no parkinsonism or sedation; propranolol stopped |
| Examination | Weight and BMI | Every visit for 6 months after starting, then quarterly (CMID: baseline, 4, 8, and 12 weeks, then quarterly) | Completed today | 64.9 kg at eight weeks, from 64.0 |
| Examination | Blood pressure | Baseline, 12 weeks, then yearly | Completed today | 120/76 |
| Laboratory | Fasting glucose and A1c | Baseline, 12 weeks to 4 months, then yearly | Up to date | Next at the three-month visit |
| Laboratory | Fasting lipid panel | Baseline, 12 weeks to 4 months, then yearly | Up to date | Next at the three-month visit |
| Laboratory | First-episode workup (MRI and EEG) | Once, in the first-episode workup | Completed today | Brain MRI normal; sleep-deprived EEG without epileptiform discharges |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodically | Completed today | PHQ-9 8, item 9 scored 0 |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan current; the 988 Suicide & Crisis Lifeline in his phone |
| Self-management | Sleep | Every visit | Completed today | Six and a half to seven hours at regular times |
| Survey | Drinking (AUDIT-C and PEth) | PEth at intake and at each check while drinking continues; AUDIT-C yearly | Completed today | PEth 122 ng/mL, from 284 |
| Medication safety | Naltrexone: liver tests and opioid exposure | Liver tests before starting, then at 1 to 3 months and every 6 to 12 months | Completed today | AST 41, ALT 37, GGT 68 U/L, improving; no opioid use |
| Medication safety | Thiamine | While drinking heavily | Completed today | Taking thiamine daily |
| Self-management | Coordinated specialty care engagement | Ongoing, for up to two to three years | Completed today | Care coordinator weekly; therapist twice; peer specialist introduced |
Goal progress:
Guideline basis: The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020); Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018); Consensus development conference on antipsychotic drugs and obesity and diabetes (2004); Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Three-month visit with fasting glucose, A1c, lipids, liver tests, PEth, and the PHQ-9. Care coordinator weekly; therapist every two weeks. Next scheduled visit 2026-04-20: three-month review with the 12-week metabolic check. [S]